MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin for metastatic breast cancer

MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin for metastatic breast cancer

Submitted by admin on February 6, 2019 - 9:48am
Source: 
Endpoints
News Tags: 
Macrogenics
metastatic breast cancer
margetuximab
clinical trials
Headline: 
MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin for metastatic breast cancer
snippet: 

MacroGenics $MGNX has claimed success in their Phase III trial of their drug margetuximab for metastatic breast cancer, putting them on the path to a BLA filing. But they’re not offering a lot of detail.

Do Not Allow Advertisers to Use My Personal information